Assessment of the Role of Everolimus Therapy in Patients with Renal Cell Carcinoma Based on Daily Routine and Recent Research Results

Anikó Maráz, András Csejtei, Judit Kocsis, Miklós Szűcs, Z. Kahán, G. Bodoky, Magdolna Dank, László Mangel, János Révész, Zoltán Varga, L. Géczi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Everolimus is indicated for adults with metastatic renal cell carcinoma (mRCC) after failure of vascular endothelial growth factor receptor-tyrosine kinase inhibitors (TKI). Currently, the therapeutic applicability of EVE has been changing. Multicenter evaluation of efficacy and safety of everolimus in daily routine and definition of patient characteristics with favorable outcome. Data of 165 patients from 9 oncology institutes in Hungary were analyzed retrospectively. Everolimus therapy was used after one TKI in 10 mg starting dose. Physical and laboratory examinations and imaging tests were performed monthly and every 3 months, respectively. Median progression-free survival (PFS) was 5.4 months. Median overall survival (OS) was 16.2 months. PFS and OS results were more favorable in patients with ECOG 0–1 (pPFS = 0.033, pOS = 0.008) and after >9 months of TKI therapy (pPFS = 0.019, pOS = 0.045). Survival was longer in nonanemic patients with ECOG 0–1 than in anemic patients with ECOG 2–3, 30.9 and 7.7 months, respectively (p = 0.029). Dose reduction and treatment delay was required in 6.2% and 8.9% of patients, respectively. Common adverse events were exanthema, edema, stomatitis, anemia, and abnormal kidney functions and glucose levels. Results of this study show that everolimus is safe and efficacious in a real-world setting. Everyday practice showed that nonanemic patients with good performance status receiving TKI therapy for >9 months are favorable candidates for this treatment. Despite the efficiency of novel, registered drugs, everolimus still plays an important role during and after second-line therapy for mRCC when availability of modern remedies is limited.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalPathology and Oncology Research
DOIs
Publication statusAccepted/In press - Oct 13 2017

Fingerprint

Renal Cell Carcinoma
Protein-Tyrosine Kinases
Research
Therapeutics
Disease-Free Survival
Survival
Stomatitis
Vascular Endothelial Growth Factor Receptor
Hungary
Everolimus
Exanthema
Physical Examination
Anemia
Edema
Kidney
Safety
Glucose
Pharmaceutical Preparations

Keywords

  • Anemia
  • ECOG
  • Everolimus
  • Metastatic kidney cancer
  • mTOR inhibitor
  • RCC

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Oncology
  • Cancer Research

Cite this

Assessment of the Role of Everolimus Therapy in Patients with Renal Cell Carcinoma Based on Daily Routine and Recent Research Results. / Maráz, Anikó; Csejtei, András; Kocsis, Judit; Szűcs, Miklós; Kahán, Z.; Bodoky, G.; Dank, Magdolna; Mangel, László; Révész, János; Varga, Zoltán; Géczi, L.

In: Pathology and Oncology Research, 13.10.2017, p. 1-8.

Research output: Contribution to journalArticle

Maráz, Anikó ; Csejtei, András ; Kocsis, Judit ; Szűcs, Miklós ; Kahán, Z. ; Bodoky, G. ; Dank, Magdolna ; Mangel, László ; Révész, János ; Varga, Zoltán ; Géczi, L. / Assessment of the Role of Everolimus Therapy in Patients with Renal Cell Carcinoma Based on Daily Routine and Recent Research Results. In: Pathology and Oncology Research. 2017 ; pp. 1-8.
@article{5564b666f66744949a356192b814c36c,
title = "Assessment of the Role of Everolimus Therapy in Patients with Renal Cell Carcinoma Based on Daily Routine and Recent Research Results",
abstract = "Everolimus is indicated for adults with metastatic renal cell carcinoma (mRCC) after failure of vascular endothelial growth factor receptor-tyrosine kinase inhibitors (TKI). Currently, the therapeutic applicability of EVE has been changing. Multicenter evaluation of efficacy and safety of everolimus in daily routine and definition of patient characteristics with favorable outcome. Data of 165 patients from 9 oncology institutes in Hungary were analyzed retrospectively. Everolimus therapy was used after one TKI in 10 mg starting dose. Physical and laboratory examinations and imaging tests were performed monthly and every 3 months, respectively. Median progression-free survival (PFS) was 5.4 months. Median overall survival (OS) was 16.2 months. PFS and OS results were more favorable in patients with ECOG 0–1 (pPFS = 0.033, pOS = 0.008) and after >9 months of TKI therapy (pPFS = 0.019, pOS = 0.045). Survival was longer in nonanemic patients with ECOG 0–1 than in anemic patients with ECOG 2–3, 30.9 and 7.7 months, respectively (p = 0.029). Dose reduction and treatment delay was required in 6.2{\%} and 8.9{\%} of patients, respectively. Common adverse events were exanthema, edema, stomatitis, anemia, and abnormal kidney functions and glucose levels. Results of this study show that everolimus is safe and efficacious in a real-world setting. Everyday practice showed that nonanemic patients with good performance status receiving TKI therapy for >9 months are favorable candidates for this treatment. Despite the efficiency of novel, registered drugs, everolimus still plays an important role during and after second-line therapy for mRCC when availability of modern remedies is limited.",
keywords = "Anemia, ECOG, Everolimus, Metastatic kidney cancer, mTOR inhibitor, RCC",
author = "Anik{\'o} Mar{\'a}z and Andr{\'a}s Csejtei and Judit Kocsis and Mikl{\'o}s Szűcs and Z. Kah{\'a}n and G. Bodoky and Magdolna Dank and L{\'a}szl{\'o} Mangel and J{\'a}nos R{\'e}v{\'e}sz and Zolt{\'a}n Varga and L. G{\'e}czi",
year = "2017",
month = "10",
day = "13",
doi = "10.1007/s12253-017-0317-0",
language = "English",
pages = "1--8",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Assessment of the Role of Everolimus Therapy in Patients with Renal Cell Carcinoma Based on Daily Routine and Recent Research Results

AU - Maráz, Anikó

AU - Csejtei, András

AU - Kocsis, Judit

AU - Szűcs, Miklós

AU - Kahán, Z.

AU - Bodoky, G.

AU - Dank, Magdolna

AU - Mangel, László

AU - Révész, János

AU - Varga, Zoltán

AU - Géczi, L.

PY - 2017/10/13

Y1 - 2017/10/13

N2 - Everolimus is indicated for adults with metastatic renal cell carcinoma (mRCC) after failure of vascular endothelial growth factor receptor-tyrosine kinase inhibitors (TKI). Currently, the therapeutic applicability of EVE has been changing. Multicenter evaluation of efficacy and safety of everolimus in daily routine and definition of patient characteristics with favorable outcome. Data of 165 patients from 9 oncology institutes in Hungary were analyzed retrospectively. Everolimus therapy was used after one TKI in 10 mg starting dose. Physical and laboratory examinations and imaging tests were performed monthly and every 3 months, respectively. Median progression-free survival (PFS) was 5.4 months. Median overall survival (OS) was 16.2 months. PFS and OS results were more favorable in patients with ECOG 0–1 (pPFS = 0.033, pOS = 0.008) and after >9 months of TKI therapy (pPFS = 0.019, pOS = 0.045). Survival was longer in nonanemic patients with ECOG 0–1 than in anemic patients with ECOG 2–3, 30.9 and 7.7 months, respectively (p = 0.029). Dose reduction and treatment delay was required in 6.2% and 8.9% of patients, respectively. Common adverse events were exanthema, edema, stomatitis, anemia, and abnormal kidney functions and glucose levels. Results of this study show that everolimus is safe and efficacious in a real-world setting. Everyday practice showed that nonanemic patients with good performance status receiving TKI therapy for >9 months are favorable candidates for this treatment. Despite the efficiency of novel, registered drugs, everolimus still plays an important role during and after second-line therapy for mRCC when availability of modern remedies is limited.

AB - Everolimus is indicated for adults with metastatic renal cell carcinoma (mRCC) after failure of vascular endothelial growth factor receptor-tyrosine kinase inhibitors (TKI). Currently, the therapeutic applicability of EVE has been changing. Multicenter evaluation of efficacy and safety of everolimus in daily routine and definition of patient characteristics with favorable outcome. Data of 165 patients from 9 oncology institutes in Hungary were analyzed retrospectively. Everolimus therapy was used after one TKI in 10 mg starting dose. Physical and laboratory examinations and imaging tests were performed monthly and every 3 months, respectively. Median progression-free survival (PFS) was 5.4 months. Median overall survival (OS) was 16.2 months. PFS and OS results were more favorable in patients with ECOG 0–1 (pPFS = 0.033, pOS = 0.008) and after >9 months of TKI therapy (pPFS = 0.019, pOS = 0.045). Survival was longer in nonanemic patients with ECOG 0–1 than in anemic patients with ECOG 2–3, 30.9 and 7.7 months, respectively (p = 0.029). Dose reduction and treatment delay was required in 6.2% and 8.9% of patients, respectively. Common adverse events were exanthema, edema, stomatitis, anemia, and abnormal kidney functions and glucose levels. Results of this study show that everolimus is safe and efficacious in a real-world setting. Everyday practice showed that nonanemic patients with good performance status receiving TKI therapy for >9 months are favorable candidates for this treatment. Despite the efficiency of novel, registered drugs, everolimus still plays an important role during and after second-line therapy for mRCC when availability of modern remedies is limited.

KW - Anemia

KW - ECOG

KW - Everolimus

KW - Metastatic kidney cancer

KW - mTOR inhibitor

KW - RCC

UR - http://www.scopus.com/inward/record.url?scp=85031426222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031426222&partnerID=8YFLogxK

U2 - 10.1007/s12253-017-0317-0

DO - 10.1007/s12253-017-0317-0

M3 - Article

C2 - 29027615

AN - SCOPUS:85031426222

SP - 1

EP - 8

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

ER -